Lipocalin-2 Protects Against Diet-Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes - PubMed (original) (raw)

. 2019 Mar 25;3(6):763-775.

doi: 10.1002/hep4.1341. eCollection 2019 Jun.

Affiliations

Lipocalin-2 Protects Against Diet-Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes

Yanyong Xu et al. Hepatol Commun. 2019.

Abstract

Hepatocytes are the major source of hepatic lipocalin-2 (LCN2), which is up-regulated in response to inflammation, injury, or metabolic stress. So far, the role of hepatocyte-derived LCN2 in the development of nonalcoholic fatty liver disease (NAFLD) remains unknown. Herein we show that overexpression of human LCN2 in hepatocytes protects against high fat/high cholesterol/high fructose (HFCF) diet-induced liver steatosis and nonalcoholic steatohepatitis by promoting lipolysis and fatty acid oxidation (FAO) and inhibiting de novo lipogenesis (DNL), lipid peroxidation, and apoptosis. LCN2 fails to reduce triglyceride accumulation in hepatocytes lacking sterol regulatory element-binding protein 1. In contrast, Lcn2-/- mice have defective lipolysis, increased lipid peroxidation and apoptosis, and exacerbated NAFLD after being fed an HFCF diet. In primary hepatocytes, Lcn2 deficiency stimulates de novo lipogenesis but inhibits FAO. Conclusion: The current study indicates that hepatocyte LCN2 protects against diet-induced NAFLD by regulating lipolysis, FAO, DNL, lipid peroxidation, and apoptosis. Targeting hepatocyte LCN2 may be useful for treatment of NAFLD.

PubMed Disclaimer

Figures

Figure 1

Figure 1

AAV‐mediated overexpression of human LCN2 in hepatocytes protects against HFCF diet–induced steatohepatitis. C57BL/6 mice were intravenously injected with AAV8‐ALB‐null or AAV8‐ALB‐hLCN2 (n = 8). The mice were then fed an HFCF diet for 20 weeks. (A) Plasma ALT and AST levels. (B) Hepatic TG levels. (C) Hepatic FFA levels. (D) Hepatic MDA levels. (E) Liver sections were used for H&E staining (left top panel), ORO (left bottom panel), sirius red staining (right top panel) or immunostaining with an antibody against F4/80 (right bottom panel) (arrows point to fibrosis [sirius red staining] or macrophages [F4/80 staining]). (F) Hepatic hydroxyproline levels (top panel) or F4/80 staining–positive area (%) (bottom panel) were quantified. In (E). *P < 0.05, **P < 0.01.

Figure 2

Figure 2

Overexpression of human LCN2 in hepatocytes regulates the hepatic genes implicated in lipogenesis, lipolysis, FAO, inflammation, and fibrogenesis. Mice have been described in the legend of Fig. 1 (n = 8). Real‐time quantitative polymerase chain reaction (PCR) was used to quantify hepatic genes involved in lipogenesis, lipolysis, FAO (A), inflammation, or fibrogenesis (B). (C) Hepatic proteins were detected by western blotting (left panel) and then quantified (right panel). (D) Plasma proteins were analyzed by western blotting (left panel) and then quantified (right panel). (E) Plasma β‐HB levels. *P < 0.05, **P < 0.01. Abbreviations: BP1c, Srebp‐1c.

Figure 3

Figure 3

Human LCN2 induces lipolysis and FAO and inhibits DNL in an LXR‐SREBP‐1‐dependent manner. (A) C57BL/6 mice were infected with AAV8‐ALB‐null or AAV8‐ALB‐hLCN2 and then fed an HFCF diet for 20 weeks (n = 8). TGH activity was determined using [3H]Triolein as substrate. (B) HepG2 cells were co‐transfected with pTK‐3 × PPRE‐luc, pCMV‐β‐gal, pCMV‐hLCN2, or pCMV‐empty. Relative luciferase activity units (RLUs) were determined after 36 hours (n = 7). (C) Primary hepatocytes were infected with Ad‐Empty or Ad‐hLCN2 for 36 hours. FAO was determined using [3H]palmitic acid as substrate (n = 6). (D) HepG2 cells were co‐transfected with pGL3‐SREBP‐1‐luc, CMV‐β‐gal, CMV‐hLCN2, or CMV‐empty in the presence or absence of the LXRα ligand T0901317 (10 µM). After 36 hours, RLUs were determined (n = 6). (E) Primary hepatocytes were isolated from Srebp1+/+ or Srebp1−/− mice, and then infected with Ad‐Empty or Ad‐hLCN2 for 48 hours. TG levels were quantified. (F) C57BL/6 mice were intravenously injected with AAV8‐ALB‐null (Null) or AAV8‐ALB‐hLCN2 (hLCN2) and then fed an HFCF diet for 20 weeks (n = 8). Four hours before euthanization, mice were intraperitoneally injected with 2H2O. Newly synthesized palmitate (PA) (left panel) or TG (right panel) levels were quantified by GC‐MS. *P < 0.05, **P < 0.01.

Figure 4

Figure 4

Loss of LCN2 exacerbates diet‐induced NAFLD. Lcn2+/+ or Lcn2−/− mice were fed an HFCF diet for 16 weeks (n = 6‐9). (A) Plasma ALT or AST levels. (B) Body or liver weight. (C) Hepatic total cholesterol or TG levels. (D) Hepatic MDA levels. (E) Representative images of H&E, ORO, or sirius red staining or immunostaining using an antibody against F4/80. (F) Hepatic hydroxyproline levels (top panel) or F4/80 staining–positive area (%) (bottom panel). Arrows point to fibrosis (sirius red staining) or macrophages (immunostaining with F4/80 antibody). *P < 0.05, **P < 0.01. Abbreviations: TC, total cholesterol.

Figure 5

Figure 5

Loss of LCN2 induces genes involved in lipogenesis, inflammation, and fibrogenesis. Lcn2+/+ or Lcn2−/− mice were fed an HFCF diet for 16 weeks (n = 6‐9). (A_‐_D) Hepatic mRNA levels involved in lipogenesis (A), lipolysis or FAO (B), inflammation (C), or fibrogenesis (D) were quantified by real‐time quantitative polymerase PCR. (E) Hepatic proteins were analyzed by western blotting (left panel) and quantified (right panel). (F) Plasma β‐HB levels (left panel) and hepatic FFA levels (right panel). *P < 0.05, **P < 0.01.

Figure 6

Figure 6

Loss of LCN2 or treatment with recombinant LCN2 protein regulates lipolysis, FAO, and lipogenesis in hepatocytes. (A) Lcn2+/+ or Lcn2−/− mice were fed an HFCF diet for 16 weeks. Hepatic TGH activity was determined (n = 7‐8). (B) FAO was determined using [3H]palmitic acid as substrate in primary hepatocytes isolated from Lcn2+/+ mice or Lcn2−/− mice (n = 6). (C) mRNA levels were quantified in primary hepatocytes isolated from Lcn2+/+ mice or Lcn2−/− mice (n = 4). (D‐F) Primary hepatocytes were isolated from Lcn2+/+ or Lcn2−/− mice and then treated with phosphate‐buffered saline (control) or 500 ng/mL LCN2 for 30 hours (n = 4‐5 per group). TGH (D) and FAO (E) were determined. The mRNA levels of genes involved in lipogenesis, FAO, or lipolysis were determined. *P < 0.05, **P < 0.01. Abbreviations: PBS, phosphate‐buffered saline.

Figure 7

Figure 7

LCN2 inhibits apoptosis. (A‐E) C57BL/6 mice were injected intravenously with AAV8‐ALB‐null or AAV8‐ALB‐hLCN2 (n = 8), and then fed an HFCF diet for 20 weeks. Lcn2+/+ or Lcn2−/− mice were fed an HFCF diet for 16 weeks (n = 6‐9). Hepatic DCF (ROS) levels were quantified (A). Hepatic protein levels were determined by western blotting (B) and then quantified (C) (top and bottom panels). Apoptosis was analyzed by TUNEL assays (D) and then quantified (E) (top and bottom panels). (F) A model for hepatocyte LCN2 to regulate the development of NAFLD. LCN2 stimulates lipolysis to release FFAs from TGH. Freshly released FFAs act as ligands for PPARα to stimulate FAO, and antagonize LXR activity to inhibit DNL. As a result, hepatic levels of FFAs, ROS, and apoptosis are reduced, leading to decreased steatosis, inflammation, and fibrosis in the liver. *P < 0.05, **P <0.01. Abbreviations: DCF, 2′,7′‐dichlorofluorescein.

References

    1. Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab 2014;25:576‐585. - PubMed
    1. Schweiger M, Lass A, Zimmermann R, Eichmann TO, Zechner R. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI‐58/ABHD5. Am J Physiol Endocrinol Metab 2009;297:E289‐E296. - PubMed
    1. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461‐1465. - PMC - PubMed
    1. Xiao X, Yeoh BS, Vijay‐Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr 2017;37:103‐130. - PubMed
    1. Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, et al. Liver is the major source of elevated serum lipocalin‐2 levels after bacterial infection or partial hepatectomy: a critical role for IL‐6/STAT3. Hepatology 2015;61:692‐702. - PMC - PubMed

Grants and funding

LinkOut - more resources